Sai Primus Lifebiotech Ltd.
SMEBSETBA
TBA
1 Shares
TBA
₹10
Financial Summary
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| 7,897.8 | 5,638.06 | |
| 96 | 34.2 | |
| 7,993.8 | 5,672.26 | |
| 6,697.14 | 4,927.69 | |
| 1,020.93 | 504.83 | |
| 736.11 | 413.93 |
Subscription Details
IPO Timeline
IPO Offer Start
TBA
IPO Offer Ends
TBA
TBA
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Funding capital expenditure towards construction of the proposed corporate office | 47.92 |
| 2 | Funding capital expenditure towards procurement of machineries for expansion | 74.542 |
| 3 | Repayment and/or pre-payment, in full or in part, of certain outstanding borrowings | 135 |
| 4 | Funding our incremental working capital requirements; and | 195 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
84.70%
Promoter stake
Offered to Public
45,00,000
shares
About the Company
We are a Contract Development and Manufacturing Organization (“CDMO”) company engaged in the manufacturing of pharmaceutical and nutraceutical products in oral solid dosage (“OSD”) with primary focus on providing third-party contract manufacturing and private labelling solutions to customers in domestic and international markets. Under these arrangements, we manufacture products based on customer requirements, agreed formulations, quality specifications, packaging requirements and applicable regulatory standards. In addition to our CDMO operations, we also undertake direct branding, wherein certain pharmaceutical and nutraceutical products are manufactured and marketed under our own brand “SPL” through distributors. Our operations cover multiple stages of the value chain, including product development, sourcing of raw materials, manufacturing, packaging, documentation, product registration support and distribution through domestic and international channels, subject to applicable regulatory requirements. Pharmaceutical refers to chemical or biological substances used for the prevention, diagnosis, treatment, or cure of disease in humans or animals. Nutraceutical refers to products derived from food sources that provide additional health benefits beyond basic nutrition, such as supporting wellness, immunity, or disease prevention.
Use of Proceeds
1. Funding capital expenditure towards construction of the proposed corporate office and guest house of our company in Tamil Nadu, India; 2. Funding capital expenditure towards procurement of machineries for expansion and upgradation of our existing manufacturing facility in Puducherry, India; 3. Repayment and/or pre-payment, in full or in part, of certain outstanding borrowings availed by our company; 4. Funding our incremental working capital requirements; and 5. General corporate purposes.
Sai Primus Lifebiotech Ltd. Latest News
News
No news found for Sai Primus Lifebiotech Ltd..
IPO FAQs
The for the Sai Primus Lifebiotech Ltd. IPO is 1 shares, which is also the minimum order quantity — you have to apply for at least 1 shares, and in multiples of 1 beyond that.
Purva Shareregistry (India) Pvt Ltd is the for the Sai Primus Lifebiotech Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them — email busicomp@vsnl.com.
Sai Primus Lifebiotech Ltd. IPO shares are proposed to be listed on BSE.
Each Sai Primus Lifebiotech Ltd. share has a of ₹10.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 84.70% of Sai Primus Lifebiotech Ltd. before the IPO.
45,00,000 shares of Sai Primus Lifebiotech Ltd. are being offered to the public in this issue.
- 1.Funding capital expenditure towards construction of the proposed corporate office and guest house of our company in Tamil Nadu, India
- 2.Funding capital expenditure towards procurement of machineries for expansion and upgradation of our existing manufacturing facility in Puducherry, India
- 3.Repayment and/or pre-payment, in full or in part, of certain outstanding borrowings availed by our company
- 4.Funding our incremental working capital requirements
- 5.General corporate purposes
Socradamus Capital Pvt Ltd. is the book running lead manager for the Sai Primus Lifebiotech Ltd. IPO.
Pre-apply means placing your Sai Primus Lifebiotech Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Sai Primus Lifebiotech Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Sai Primus Lifebiotech Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.